Suhani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Suhani has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Lalit Aggarwal
Department of General Surgery, Lady Hardinge Medical College, New Delhi, India
4 shared publicationsShadan Ali
Department of General Surgery, Lady Hardinge Medical College, New Delhi, India
4 shared publicationsShaji Thomas
Department of General Surgery, Lady Hardinge Medical College, New Delhi, India
4 shared publicationsKusum Meena
Department of General Surgery, Lady Hardinge Medical College, New Delhi, India
3 shared publicationsRajinder Parshad
Surgical Disciplines
3 shared publicationsMohit Joshi
Surgical Disciplines
2 shared publications
Latest Publications
- 6 May 2026
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
Redefining bone metastasis imaging in breast cancer: whole body low-dose computed tomography compared with skeletal scintigraphy in a real-world cohort
Background: Skeletal scintigraphy is standard imaging to detect bone metastasis in breast cancer. Nuclear medicine facilities are limited in availability. As an alternative diagnostic modality, we evaluated whole-body low dose computed tomography (WBLDCT) scan for detection of bone metastasis. Methods: This cross-sectional exploratory study was conducted from November 2021 to May 2023 with an aim to study the clinical applicability of WBLDCT for detecting bone metastasis in patients with breast cancer. Patients with primary tumor measuring 5 cm or more, pathologically proven axillary lymph node metastasis, Stage III/IV disease, symptoms attributable to metastasis and suspected disease recurrence were included. Patients underwent WBLDCT and bone scan within 2 weeks. WBLDCT was done during the same time as conventional dose CT scan done as part of metastatic workup. Image analysis was performed by radiology and nuclear medicine experts in blinded fashion. Agreement amongst WBLDCT, bone scan and combination of these was calculated using inter-rater agreement. Results: One hundred seven patients underwent WBLDCT and bone scan. The mean age was 48.5 years and three-fourth had Stage III disease. Both bone scan and WBLDCT detected bone metastasis in 19 patients. Bone scan picked up additional metastasis in two patients. WBLDCT detected bone metastasis additionally in three patients. Specificity of bone scan and WBLDCT was 87.5 and 91.7%, respectively. Concordance rate of bone scan and WBLDCT with the combination was 0.889 and 0.945, respectively. Conclusion: WBLDCT can be used as an alternative imaging modality to detect bone metastasis in breast cancer patients.
- 6 May 2026
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
Redefining bone metastasis imaging in breast cancer: whole body low-dose computed tomography compared with skeletal scintigraphy in a real-world cohort
Background: Skeletal scintigraphy is standard imaging to detect bone metastasis in breast cancer. Nuclear medicine facilities are limited in availability. As an alternative diagnostic modality, we evaluated whole-body low dose computed tomography (WBLDCT) scan for detection of bone metastasis. Methods: This cross-sectional exploratory study was conducted from November 2021 to May 2023 with an aim to study the clinical applicability of WBLDCT for detecting bone metastasis in patients with breast cancer. Patients with primary tumor measuring 5 cm or more, pathologically proven axillary lymph node metastasis, Stage III/IV disease, symptoms attributable to metastasis and suspected disease recurrence were included. Patients underwent WBLDCT and bone scan within 2 weeks. WBLDCT was done during the same time as conventional dose CT scan done as part of metastatic workup. Image analysis was performed by radiology and nuclear medicine experts in blinded fashion. Agreement amongst WBLDCT, bone scan and combination of these was calculated using inter-rater agreement. Results: One hundred seven patients underwent WBLDCT and bone scan. The mean age was 48.5 years and three-fourth had Stage III disease. Both bone scan and WBLDCT detected bone metastasis in 19 patients. Bone scan picked up additional metastasis in two patients. WBLDCT detected bone metastasis additionally in three patients. Specificity of bone scan and WBLDCT was 87.5 and 91.7%, respectively. Concordance rate of bone scan and WBLDCT with the combination was 0.889 and 0.945, respectively. Conclusion: WBLDCT can be used as an alternative imaging modality to detect bone metastasis in breast cancer patients.
- 18 February 2025
- Published by Springer Nature in Hernia
- Vol. 29 (1) , 1-11
Penetrating fixation device versus fibrin sealant for mesh fixation in laparoscopic repair of ventral hernia: a randomized controlled trial
Purpose Post-operative pain following intra peritoneal onlay mesh (IPOM) repair of ventral hernia is commonly attributed to mechanical fixation devices. Fibrin sealant is a novel technique of mesh fixation purported to cause less pain. The aim of this study was to compare postoperative pain in these two methods of mesh fixation. Methods This was a double-blinded, randomized controlled trial. Eighty patients with primary ventral hernia underwent laparoscopic IPOM repair using PROCEED™ mesh, which was fixed with either mechanical fixation device, SECURESTRAP™ (MF group) or fibrin sealant, TISSEEL™ (FS group). Primary end point was postoperative pain at rest and movement on a Visual Analogue Scale (VAS) of 0–10. Operative time, recurrence, seroma and quality of life (QoL) were secondary outcomes. Patients were followed up for one year. Results There was no significant difference in pain score at 12 h, 24 h, 7 days, 1, 3 and 12 months between the groups, except pain on movement, which was significantly less in the FS group on the seventh day (median VAS 3 vs. 2, p = 0.01). Mean operative time was 8 min longer in the FS group (p = 0.001). Two patients in the FS and none in the MF group had recurrence at one year (p = 0.18). Seroma formation, postoperative QoL and patient satisfaction scores were similar in both groups. Conclusions Use of fibrin sealant for mesh fixation does not provide significant advantage over mechanical fixation in laparoscopic IPOM repair.
- 18 February 2025
- Published by Springer Nature in Hernia
- Vol. 29 (1) , 1-11
Penetrating fixation device versus fibrin sealant for mesh fixation in laparoscopic repair of ventral hernia: a randomized controlled trial
Purpose Post-operative pain following intra peritoneal onlay mesh (IPOM) repair of ventral hernia is commonly attributed to mechanical fixation devices. Fibrin sealant is a novel technique of mesh fixation purported to cause less pain. The aim of this study was to compare postoperative pain in these two methods of mesh fixation. Methods This was a double-blinded, randomized controlled trial. Eighty patients with primary ventral hernia underwent laparoscopic IPOM repair using PROCEED™ mesh, which was fixed with either mechanical fixation device, SECURESTRAP™ (MF group) or fibrin sealant, TISSEEL™ (FS group). Primary end point was postoperative pain at rest and movement on a Visual Analogue Scale (VAS) of 0–10. Operative time, recurrence, seroma and quality of life (QoL) were secondary outcomes. Patients were followed up for one year. Results There was no significant difference in pain score at 12 h, 24 h, 7 days, 1, 3 and 12 months between the groups, except pain on movement, which was significantly less in the FS group on the seventh day (median VAS 3 vs. 2, p = 0.01). Mean operative time was 8 min longer in the FS group (p = 0.001). Two patients in the FS and none in the MF group had recurrence at one year (p = 0.18). Seroma formation, postoperative QoL and patient satisfaction scores were similar in both groups. Conclusions Use of fibrin sealant for mesh fixation does not provide significant advantage over mechanical fixation in laparoscopic IPOM repair.
- Open Access
- 1 January 2024
- Published by Wiley in Biochemistry Research International
- Vol. 2024 (1) , 5584607
Exploring Molecular Alterations in Breast Cancer Among Indian Women Using Label‐Free Quantitative Serum Proteomics
The clinical data indicate that diverse parameters characterize breast cancer patients in India, including age at presentation, risk factors, outcomes, and behavior. Alarming incidence and mortality rates emphasize the crucial need for early screening measures to combat breast cancer‐related deaths effectively. Quantitative proteomic approaches prove pivotal in predicting cancer prognosis, analyzing protein expression patterns tied to disease aggressiveness and metastatic potential, and facilitating conversant therapy selection. Thus, this study was envisioned with the goal of identifying protein markers associated with breast cancer in Indian women, which could potentially be developed as diagnostic tools and therapeutic targets in the future. Applying label‐free proteomic quantitation method and statistical analysis, several differentially expressed proteins (DEPs) were identified in the serum of breast cancer patients compared to controls, including SBSN, ANG, PCOLCE, and WFDC3 (upregulated), and PFN1, FLNA, and DSG2 (downregulated). The expression of SBSN was also validated by western blotting. Statistical methods were employed to proteomic expression data, which highlighted the ability of DEPs to distinguish between breast cancer and control samples. Conclusively, this study recognizes prospective biomarkers for breast cancer among Indian women and highlights the requisite of in‐depth functional studies to elucidate their precise roles in breast cancer development. We particularly emphasize on SBSN and PFN1, as these proteins were observed to be progressively overexpressed and under expressed, respectively, in breast cancer samples compared to control samples, ranging from early‐stage to metastatic cases.
- 1 January 2024
- Published by Wiley in Biochemistry Research International
- Vol. 2024 (1) , 5584607
Open AccessExploring Molecular Alterations in Breast Cancer Among Indian Women Using Label‐Free Quantitative Serum Proteomics
The clinical data indicate that diverse parameters characterize breast cancer patients in India, including age at presentation, risk factors, outcomes, and behavior. Alarming incidence and mortality rates emphasize the crucial need for early screening measures to combat breast cancer‐related deaths effectively. Quantitative proteomic approaches prove pivotal in predicting cancer prognosis, analyzing protein expression patterns tied to disease aggressiveness and metastatic potential, and facilitating conversant therapy selection. Thus, this study was envisioned with the goal of identifying protein markers associated with breast cancer in Indian women, which could potentially be developed as diagnostic tools and therapeutic targets in the future. Applying label‐free proteomic quantitation method and statistical analysis, several differentially expressed proteins (DEPs) were identified in the serum of breast cancer patients compared to controls, including SBSN, ANG, PCOLCE, and WFDC3 (upregulated), and PFN1, FLNA, and DSG2 (downregulated). The expression of SBSN was also validated by western blotting. Statistical methods were employed to proteomic expression data, which highlighted the ability of DEPs to distinguish between breast cancer and control samples. Conclusively, this study recognizes prospective biomarkers for breast cancer among Indian women and highlights the requisite of in‐depth functional studies to elucidate their precise roles in breast cancer development. We particularly emphasize on SBSN and PFN1, as these proteins were observed to be progressively overexpressed and under expressed, respectively, in breast cancer samples compared to control samples, ranging from early‐stage to metastatic cases.
- 12 May 2023
- Published by Wiley in World Journal of Surgery
- Vol. 47 (9) , 2178-2185
Evaluation of Dual Dye Technique for Sentinel Lymph Node Biopsy in Breast Cancer: Two‐Arm Open‐Label Parallel Design Non‐Inferiority Randomized Controlled Trial
Introduction: Radioisotope and blue dye are standard agents for performing sentinel lymph node (SLN) biopsy in breast cancer. The paucity of nuclear medicine facility poses logistic challenge. This study evaluated performance of radioisotope & methylene blue (MB) with indocyanine green (ICG) and MB for SLNB. Patients and Methods: This randomized controlled trial was conducted from December 2019 to July 2022 comparing SLN identification proportions of radioisotope‐blue dye [Group A] with dual dye (MB + ICG; Group B]. Secondary objective included time required and cost effectiveness of performing SLNB. Sample size of 70 (35 in each arm) was calculated. Upfront operable node negative early breast cancer was included in the study. Clinico‐demographic data, number & type of SLN, time taken were noted. Cost analysis was done including the equipment, manpower & consumables. Chi‐square/Fisher exact test was used to compare proportion between two groups. p value of less than 0.05 was considered to represent statistical significance.Results: Seventy patients randomized to either group were similar in clinico‐demographic and tumor characteristics. SLN identification rate (IR) was 91.43% in group A and 100% in group B. Overall IR of MB, radioisotope and ICG were 91.43%, 91.43% and 100%, respectively. Mean number of SLNs identified were 3 in group A and 4 in group B. Median time required for SLNB was 12 min and 14 min in either group, respectively. Cost of performing SLNB was higher in Group B.Conclusion: SLNB using dual dye is non‐inferior to radioisotope‐blue dye in upfront operable early breast cancer.Trial registration number Clinical Trial registry India CTRI/2020/02/023503.
- 12 May 2023
- Published by Wiley in World Journal of Surgery
- Vol. 47 (9) , 2178-2185
Evaluation of Dual Dye Technique for Sentinel Lymph Node Biopsy in Breast Cancer: Two‐Arm Open‐Label Parallel Design Non‐Inferiority Randomized Controlled Trial
Introduction: Radioisotope and blue dye are standard agents for performing sentinel lymph node (SLN) biopsy in breast cancer. The paucity of nuclear medicine facility poses logistic challenge. This study evaluated performance of radioisotope & methylene blue (MB) with indocyanine green (ICG) and MB for SLNB. Patients and Methods: This randomized controlled trial was conducted from December 2019 to July 2022 comparing SLN identification proportions of radioisotope‐blue dye [Group A] with dual dye (MB + ICG; Group B]. Secondary objective included time required and cost effectiveness of performing SLNB. Sample size of 70 (35 in each arm) was calculated. Upfront operable node negative early breast cancer was included in the study. Clinico‐demographic data, number & type of SLN, time taken were noted. Cost analysis was done including the equipment, manpower & consumables. Chi‐square/Fisher exact test was used to compare proportion between two groups. p value of less than 0.05 was considered to represent statistical significance.Results: Seventy patients randomized to either group were similar in clinico‐demographic and tumor characteristics. SLN identification rate (IR) was 91.43% in group A and 100% in group B. Overall IR of MB, radioisotope and ICG were 91.43%, 91.43% and 100%, respectively. Mean number of SLNs identified were 3 in group A and 4 in group B. Median time required for SLNB was 12 min and 14 min in either group, respectively. Cost of performing SLNB was higher in Group B.Conclusion: SLNB using dual dye is non‐inferior to radioisotope‐blue dye in upfront operable early breast cancer.Trial registration number Clinical Trial registry India CTRI/2020/02/023503.
- 1 January 2021
- Published by Medknow in Indian Journal of Cancer
- Vol. 58 (1) , 35-37
Advances in breast cancer research in 2020: changes in clinical practice
- 1 January 2021
- Published by Medknow in Indian Journal of Cancer
- Vol. 58 (1) , 35-37
Advances in breast cancer research in 2020: changes in clinical practice
- 13 September 2017
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 79 (6) , 574-575
Skin Incision for Port Placement in Laparoscopic Surgery—an Often Forgotten Critical Step!
Port placement is the first and one of the most important step in laparoscopic surgeries. However, these incisions for port placement are often placed casually leading to larger or smaller incisions than those required. Larger incisions may lead to problems like oozing from skin incisions, egress of gas used to create pneuomoperitoneum, while smaller incisions lead to difficulty in port introduction and incision site skin necrosis. We describe a simple and novel technique of giving proper sized skin incision to avoid such problems.
- 13 September 2017
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 79 (6) , 574-575
Skin Incision for Port Placement in Laparoscopic Surgery—an Often Forgotten Critical Step!
Port placement is the first and one of the most important step in laparoscopic surgeries. However, these incisions for port placement are often placed casually leading to larger or smaller incisions than those required. Larger incisions may lead to problems like oozing from skin incisions, egress of gas used to create pneuomoperitoneum, while smaller incisions lead to difficulty in port introduction and incision site skin necrosis. We describe a simple and novel technique of giving proper sized skin incision to avoid such problems.
- 11 July 2017
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 79 (5) , 446-449
Mammographic Screening or Breast Cancer Awareness? Time to Ponder
Breast cancer in India is becoming the leading cause of cancer-related mortality in urban women. In developed countries, the mortality from breast cancer has decreased in the past few years attributable to better awareness of disease, screening programs, early detection and more effective treatment available. Although widely used, the screening programs running in the western countries have been a point of criticism in the recent years as they lead to increased healthcare cost and detection of otherwise benign and clinically insignificant breast lesion (both benign and malignant). Also in a developing country like ours where the awareness about breast cancer among the ladies is itself poor, whether screening is feasible and cost-effective is a matter of ongoing debate. We conducted this literature review to ascertain the importance of breast cancer awareness, breast self-examination, and clinical breast examination as effective screening tools in a resource deficient country like India.
- 11 July 2017
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 79 (5) , 446-449
Mammographic Screening or Breast Cancer Awareness? Time to Ponder
Breast cancer in India is becoming the leading cause of cancer-related mortality in urban women. In developed countries, the mortality from breast cancer has decreased in the past few years attributable to better awareness of disease, screening programs, early detection and more effective treatment available. Although widely used, the screening programs running in the western countries have been a point of criticism in the recent years as they lead to increased healthcare cost and detection of otherwise benign and clinically insignificant breast lesion (both benign and malignant). Also in a developing country like ours where the awareness about breast cancer among the ladies is itself poor, whether screening is feasible and cost-effective is a matter of ongoing debate. We conducted this literature review to ascertain the importance of breast cancer awareness, breast self-examination, and clinical breast examination as effective screening tools in a resource deficient country like India.
- 1 January 2015
- Published by SAGE Publications in Breast Disease
- Vol. 35 (1) , 25-27
Squamous cell carcinoma arising in epidermal inclusion cyst of breast: A diagnostic dilemma
Epidermal, or inclusion, cysts are frequently seen benign lesions that are lined with stratified squamous epithelium. Malignant transformation of these is rare, occurring in 0.011% to 0.045% cases [1]. We herein report an unusual case of squamous cel
- 1 January 2015
- Published by SAGE Publications in Breast Disease
- Vol. 35 (1) , 25-27
Squamous cell carcinoma arising in epidermal inclusion cyst of breast: A diagnostic dilemma
Epidermal, or inclusion, cysts are frequently seen benign lesions that are lined with stratified squamous epithelium. Malignant transformation of these is rare, occurring in 0.011% to 0.045% cases [1]. We herein report an unusual case of squamous cel
- 1 January 2014
- Published by SAGE Publications in Breast Disease
- Vol. 34 (3) , 95-99
Primary neuroendocrine carcinoma breast: Our experience
Objectives: This retrospective study was designed to present the clinical characteristics and histopathological features of Primary neuroendocrine carcinoma (PNEC) of breast, and to evaluate the impact on outcome following its management on the line
- 1 January 2014
- Published by SAGE Publications in Breast Disease
- Vol. 34 (3) , 95-99
Primary neuroendocrine carcinoma breast: Our experience
Objectives: This retrospective study was designed to present the clinical characteristics and histopathological features of Primary neuroendocrine carcinoma (PNEC) of breast, and to evaluate the impact on outcome following its management on the line
- 1 January 2014
- Published by SAGE Publications in Breast Disease
- Vol. 34 (3) , 135-138
Denovo malignant fibrous histiocytoma of breast: Report of a case and review of literature
Sarcomas are rare histological types of malignancy found in the breast. While angiosarcoma is the most common type of sarcoma found here, malignant fibrous histiocytoma (MFH) arising de novo is one of the rare varieties. We recently cared for a middl
- 1 January 2014
- Published by SAGE Publications in Breast Disease
- Vol. 34 (3) , 135-138
Denovo malignant fibrous histiocytoma of breast: Report of a case and review of literature
Sarcomas are rare histological types of malignancy found in the breast. While angiosarcoma is the most common type of sarcoma found here, malignant fibrous histiocytoma (MFH) arising de novo is one of the rare varieties. We recently cared for a middl